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•  understanding of opioid dependence in adults. 
•  inter-individual variability in response to MD: 
o Impact of genetic variability. 
• Drug targets/receptors (OPRM1) ? 
• Drug transporters (ABCB1)  
• Metabolising enzymes (CYP2D6) ? 
• Immune response (IL-1B)  
o Glial activation  release of immune mediators incl. proinflammatory 
cytokines interleukin-1 beta (IL-1β), creates proinflammatory 
environment  neuronal excitability to  opioid reward and 
dependence.  
Neonatal abstinence syndrome (NAS) in methadone exposed infants: role of genetic variability 
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• Methadone (MD): 
o Currently the only FDA/TGA 
“approved” opioid 
substitution therapy during 
pregnancy. 
o Advantages:  obstetric 
complications,  prenatal 
care,  maternal nutrition, 
drug seeking environment. 
o Disadvantages: Neonatal 
Abstinence Syndrome (NAS). 
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• Despite  knowledge on the impact of genetic variability on MD 
response, the underlying mechanisms explaining NAS largely undefined: 
o ? genetic variability.  
 
• By assessing genetic variability in mothers and infants, the association 
between genetic variability and NAS could be used as a predictive tool: 
o =  management of the infant by potentially  morphine administered 




• Despite impact of IL-1B and OPRM1 genetic variability on opioid response in 
adults, this was not observed in infants.  
• Limitation: small sample size to date.  
• This study of possible impact of IL-1B and OPRM1 genetic variability on NAS is 




Opioid dependence in pregnancy Understanding opioid dependence Genetic variability and NAS 
Nature vs Nurture Infant characteristics 
• Investigate the impact of IL-1B -31 and OPRM1 A118G genetic variability 
on NAS incidence (treatment required) & severity (dose of morphine). 
Aim 
Dependence = genetics + environment 
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Genotyping for OPRM1 and IL-1B 
• Infant buccal swab: DNA isolated from 
cheek cells, genotyped 
 
• Genetic markers: 
o OPRM1 A118G: Wild-type (WT) 
associated with  response to 
opioids 
 
o Immune response, IL-1B -31 
promoter mutation: Wild-type (WT) 
associated with  IL-1β expression 
• 71 methadone exposed 
infants; 46 with NAS; 26 
with genetic & morphine 
treatment data.  
 
• No difference in IL-1B or 
OPRM1 genotypes 
between infants with & 
without NAS, OR (p): 
 
IL-1B: 1.9 (0.21) 
  
OPRM1:0.23 (0.24) 
IL-1B -31 Infant genotype  (morphine (mg), median (range)) 
WT (n=21) > 1 Var (n=5) WT (n=21) > 1 Var (n=5) WT (n=20) > 1 Var (n=5) 
0.15 (0.1-0.4) 0.2 (0.14-0.3) 0.3 (0.17-0.66) 0.28 (0.23-0.68) 33.8 (14.3-79.3) 34.8 (26.7-91.8) 
Initial morphine (p=0.06) Max morphine (p=0.94) Total morphine (p=0.67) 
OPRM1 A118G Infant genotype (morphine (mg), median (range)) 
WT (n=24) > 1 Var (n=2) WT (n=24) > 1 Var (n=2) WT (n=23) > 1 Var (n=2) 
0.17 (0.1-0.4) 0.22 (0.13-0.3) 0.29 (0.17-0.68) 0.24 (0.18-0.3) 34.8 (14.3-91.8) 25.4 (19.4-31.5) 
Initial morphine (p=0.73) Max morphine (p=0.39) Total morphine (p=0.38) 
Maternal methadone dose at delivery: mg (median (range)) 120 (20-220) 
Gestational age: weeks (median (range)) 
• Premature (n (%)) 
39 (35-41) 
2 (8) 
Gender male (n (%)) 14 (54) 
Birth weight: g (median (range)) 
• Low birth weight (n (%)) 
2963 (2157-3883) 
5 (19) 






Adjunctive phenobarb (n (%)) 6 (23) 
